Skip to main content

TRINITY BIOTECH PLC

corporate_fare Company Profile

TRINITY BIOTECH PLC

TRIB·NASDAQ·Life Sciences·CIK 0000888721

Trinity Biotech plc is a biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors. The company was incorporated in Ireland in 1992 and its ADSs have traded on the Nasdaq Global Market under the symbol "TRIB" since October 1992. Following the acquisition of the biosensor assets of Waveform Technologies Inc. in 2024, Trinity Biotech has been developing a range of biosensor devices and related services, starting with a continuous glucose monitoring product. Through its subsidiaries, the company develops, acquires, manufactures, and markets medical diagnostic products for the clinical laboratory and point of care segments of the diagnostic market. These products are used to detect autoimmune, infectious, and sexually transmitted diseases, disorders of the liver and intestine, and to monitor markers for diabetes. Trinity Biotech markets its portfolio of several hundred products to customers in approximately 100 countries globally through its own sales force and a network of international distributors and strategic partners.

TRINITY BIOTECH PLC (NASDAQ:TRIB) is a publicly traded company in the Life Sciences sector. Wiseek monitors TRIB SEC EDGAR filings and licensed market news in real time, scoring each submission for market-moving significance on a 1–10 scale. Items rated 7 or higher generate instant alerts.

Recent high-impact activity:

  • Trinity Biotech Secures Global Product Recognition and Strategic Manufacturing Approval
  • Perceptive Credit Holdings Sells $2 Million in Trinity Biotech ADSs
  • Trinity Biotech Finalizes Terms for Highly Dilutive Debt-to-Equity Conversion and Resale of 55.9M ADSs
  • Trinity Biotech Registers Secondary Offering of 55.9M ADSs for Debt Conversion, Signaling Substantial Dilution

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$43.78M
Net Income
-$37.38M
Op. Cash Flow
-$5.93M
Free Cash Flow
-$6.02M
Gross Profit
$16.89M
Operating Income
-$15.79M
Cash & Equivalents
$5.14M
Total Debt
$210K
Debt / Equity
-0.00×
Net Margin
-85.4%
Source: 20-F · filed 2026-04-30 · accession 0001554855-26-000848

Insider Transactions

TRIB files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.

$0.7008
52-week range · as of 2026-05-26 $0.5012 – $3.44
Market cap
$14.16M
Volume
58.7K (0.6× avg)
3-mo avg 101.1K
Live data · 2026-06-03 15:14 UTC · Market open

show_chartPrice Chart

Loading chart...

feed TRIB - Filings & News (Page 2)

TRIB
Feb 13, 2026, 3:18 PM EST
Filing Type: 6-K
Importance Score:
8
Trinity Biotech Secures Global Product Recognition and Strategic Manufacturing Approval
Sentiment: Positive
View Wiseek Article
TRIB
Jan 26, 2026, 5:19 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Perceptive Credit Holdings Sells $2 Million in Trinity Biotech ADSs
Sentiment: Negative
View Wiseek Article
TRIB
Jan 23, 2026, 5:14 PM EST
Filing Type: 424B3
Importance Score:
9
Trinity Biotech Finalizes Terms for Highly Dilutive Debt-to-Equity Conversion and Resale of 55.9M ADSs
Sentiment: Negative
View Wiseek Article
TRIB
Jan 15, 2026, 4:27 PM EST
Filing Type: F-1
Importance Score:
8
Trinity Biotech Registers Secondary Offering of 55.9M ADSs for Debt Conversion, Signaling Substantial Dilution
Sentiment: Negative
View Wiseek Article